The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer

Takakura, Kazuki; Kawamura, Atsushi; Torisu, Yuichi; Koido, Shigeo; Yahagi, Naohisa; Saruta, Masayuki

doi:10.3390/ijms20133331

Cited by 41 publications

(21 citation statements)

References 119 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the burgeoning SELEX technology makes it possible to select personalized aptamers for each patient. It has been reported that primary cancerous cells and biopsies directly originating from patients have been used for individual tumor-specific aptamer selection ( Liu et al, 2019 ; Takakura et al, 2019 ; Zamay et al, 2019 ). Additionally, organoid technology has become one of the most important breakthroughs, so patient-derived tumoroid-based SELEX is likely to exhibit exciting potential prospects for personalized ApDC treatment.…”

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Paclitaxel (PTX) has been used for cancer treatment for decades and has become one of the most successful chemotherapeutics in the clinic and financially. However, serious problems with its use still exist, owing to its poor solubility and non-selective toxicity. With respect to these issues, recent advances have addressed the water solubility and tumor specificity related to PTX application. Many measures have been proposed to remedy these limitations by enhancing tumor recognition via ligand-receptor-mediated targeting as well as other associated strategies. In this review, we investigated various kinds of ligands that have emerged as PTX tumor-targeting tools. In particular, this article highlights small molecule-, protein-, and aptamer-functionalized conjugates and nanoparticles (NPs), providing a promising approach for PTX-based individualized treatment prospects.

show abstract

Section: Discussion and Future Perspectivesmentioning

confidence: 99%

Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

show abstract

“…Several aptamers are currently in various stages of clinical trials for therapy of hematological [ 1 ] and pancreatic cancer [ 177 ] diseases. Pi et al [ 178 ] also reported preparation of RNA/DNA hybrid nanoparticles that contained DNA aptamer specific to annexin A2 in ovarian cancer cells.…”

Section: Dna/rna Aptamers: Structure and Propertiesmentioning

confidence: 99%

Polymer Nanoparticles and Nanomotors Modified by DNA/RNA Aptamers and Antibodies in Targeted Therapy of Cancer

2021

View full text Add to dashboard Cite

Polymer nanoparticles and nano/micromotors are novel nanostructures that are of increased interest especially in the diagnosis and therapy of cancer. These structures are modified by antibodies or nucleic acid aptamers and can recognize the cancer markers at the membrane of the cancer cells or in the intracellular side. They can serve as a cargo for targeted transport of drugs or nucleic acids in chemo- immuno- or gene therapy. The various mechanisms, such as enzyme, ultrasound, magnetic, electrical, or light, served as a driving force for nano/micromotors, allowing their transport into the cells. This review is focused on the recent achievements in the development of polymer nanoparticles and nano/micromotors modified by antibodies and nucleic acid aptamers. The methods of preparation of polymer nanoparticles, their structure and properties are provided together with those for synthesis and the application of nano/micromotors. The various mechanisms of the driving of nano/micromotors such as chemical, light, ultrasound, electric and magnetic fields are explained. The targeting drug delivery is based on the modification of nanostructures by receptors such as nucleic acid aptamers and antibodies. Special focus is therefore on the method of selection aptamers for recognition cancer markers as well as on the comparison of the properties of nucleic acid aptamers and antibodies. The methods of immobilization of aptamers at the nanoparticles and nano/micromotors are provided. Examples of applications of polymer nanoparticles and nano/micromotors in targeted delivery and in controlled drug release are presented. The future perspectives of biomimetic nanostructures in personalized nanomedicine are also discussed.

show abstract

“…Another group reported that AZD9150 increases drug sensitivity and decreases tumorigenicity in neuroblastomas [170]. Recruitment for AZD9150 trials in colorectal, pancreatic, and lung cancer is ongoing (NCT02983578) [171].…”

Section: Therapeutic Options Against Tumorigenic Fam72: Rna Interferementioning

confidence: 99%

FAM72, Glioblastoma Multiforme (GBM) and Beyond

Rahane

Pramanik

et al. 2021

Cancers

View full text Add to dashboard Cite

Neural stem cells (NSCs) offer great potential for regenerative medicine due to their excellent ability to differentiate into various specialized cell types of the brain. In the central nervous system (CNS), NSC renewal and differentiation are under strict control by the regulation of the pivotal SLIT-ROBO Rho GTPase activating protein 2 (SRGAP2)—Family with sequence similarity to the 72 (FAM72) master gene (i.e., |-SRGAP2–FAM72-|) via a divergent gene transcription activation mechanism. If the gene transcription control unit (i.e., the intergenic region of the two sub-gene units, SRGAP2 and FAM72) gets out of control, NSCs may transform into cancer stem cells and generate brain tumor cells responsible for brain cancer such as glioblastoma multiforme (GBM). Here, we discuss the surveillance of this |-SRGAP2–FAM72-| master gene and its role in GBM, and also in light of FAM72 for diagnosing various types of cancers outside of the CNS.

show abstract

The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer

Cited by 41 publications

References 119 publications

Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy

Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy

Polymer Nanoparticles and Nanomotors Modified by DNA/RNA Aptamers and Antibodies in Targeted Therapy of Cancer

FAM72, Glioblastoma Multiforme (GBM) and Beyond

Contact Info

Product

Resources

About